{"id":"intravenous-levonadifloxacin-linezolid-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Peripheral neuropathy (linezolid-related)"},{"rate":null,"effect":"Thrombocytopenia (linezolid-related)"},{"rate":null,"effect":"QT prolongation (fluoroquinolone-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levonadifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. The combination provides synergistic activity against resistant pathogens, particularly gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).","oneSentence":"This combination drug pairs a fluoroquinolone antibiotic (levonadifloxacin) that inhibits bacterial DNA gyrase with linezolid, an oxazolidinone that inhibits bacterial protein synthesis, to provide broad-spectrum coverage against gram-positive and gram-negative bacteria.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:56.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated skin and soft tissue infections"},{"name":"Hospital-acquired pneumonia"},{"name":"Community-acquired pneumonia with resistant pathogens"}]},"trialDetails":[{"nctId":"NCT03405064","phase":"PHASE3","title":"Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Wockhardt","startDate":"2017-08-25","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":501}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous Levonadifloxacin/Linezolid Infusion","genericName":"Intravenous Levonadifloxacin/Linezolid Infusion","companyName":"Wockhardt","companyId":"wockhardt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug pairs a fluoroquinolone antibiotic (levonadifloxacin) that inhibits bacterial DNA gyrase with linezolid, an oxazolidinone that inhibits bacterial protein synthesis, to provide broad-spectrum coverage against gram-positive and gram-negative bacteria. Used for Complicated skin and soft tissue infections, Hospital-acquired pneumonia, Community-acquired pneumonia with resistant pathogens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}